A — Agilent Technologies, Inc.

The Street is constructive, but the tape is consolidating. Q3 FY26 (reported 2026-08-26) was a clean beat-and-raise: revenue of $1.878B vs. ~$1.84B consensus (+8.1% reported, +7.3% core), adjusted EPS of $1.62 vs. $1.49 expected, segment operating margins up ~600bps to 23.5%, and FY26 adjusted EPS guidance lifted to $6.18-$6.21. That triggered an aggressive round of target hikes (JPM to $190, RBC to $185, TD Cowen to $180, Barclays to $175), with the consensus at ~$170-172 and 33 of 41 raters at Buy. Yet as of 2026-09-13 the stock sits 2.96% below its 20-day SMA, -0.88% over one month and -2.61% over the past week — a classic post-earnings 'good news already priced' digestion rather than a rejection of the results.

The trend inflected in FY25 and has held — this is not a blip. Quarterly revenue went $1.578B (Q3 FY24) → $1.701B (Q4 FY24) → $1.681B (Q1 FY25) → $1.668B (Q2 FY25) → $1.738B (Q3 FY25) → $1.861B (Q4 FY25) → $1.798B (Q1 FY26) → $1.835B (Q2 FY26) → $1.878B (Q3 FY26), a new record. YoY growth has printed +1.4%, +6.0%, +10.1%, +9.4%, +7.0%, +10.0%, +8.1% over the last seven quarters — a genuine acceleration out of the FY24 destocking trough (which saw revenue fall from $1.688B in Q4 FY23 to $1.578B in Q3 FY24) into a stable 7-10% growth band. Margins are expanding with the volume: gross margin was 55.5% in Q3 FY26 vs. 52.6% a year earlier, and TTM operating margin is 22.2% vs. 21.3% a year ago (GAAP; management's adjusted operating margin is above 26%). Earnings are following: TTM GAAP EPS is $5.11, while FY26 adjusted guidance of $6.18-$6.21 implies roughly 10-12% growth, and Q3 FY26 operating cash flow of $519M was +43% YoY with FCF of $439M vs. $259M. One caveat: Q1 FY26 GAAP operating margin dipped to 19.6% from 22.4% in Q1 FY25, and Q4 FY25 net income of $434M benefited from a very low tax rate — so quarter-to-quarter GAAP EPS is noisy and the TTM/OCF numbers are the cleaner read.

Fair, with a modest discount to its own history. At the 2026-09-13 price of $146.93, the TTM GAAP P/E is 28.9x vs. a 5-year average of 31.6x (~9% below), and P/S is 5.63 vs. a 5-year average of 5.96 (~6% below) — which is why the deterministic overlay labels this 'Neutral vs. its own history,' not cheap. On forward numbers the picture improves: 23.7x the midpoint of FY26 adjusted EPS guidance, or ~21x if FY27 EPS lands near $6.90 (+11-12%). PEG of 1.53 is reasonable but not a bargain. The offset is EV/EBITDA of 22.2x (ratio_values), which is a premium to where large-cap life-science tools peers typically trade, and a TTM FCF yield of only ~3.0% ($1.25B FCF / $41.5B cap) with a 0.76% dividend yield. Net: you are paying a fair price for a quality compounder, not getting a discount to the sector.

The market has already paid for the recovery in price but not in multiple. The stock is up 31.76% over six months and 13.16% over three months, and sits ~36% above its 52-week low of $108.35 — so the demand inflection is reflected in the share price. But the multiple is still below its own 5-year average, meaning the earnings recovery is only partly capitalized. That creates an asymmetric setup around the late-November Q4 FY26 print (tentatively 2026-11-23): delivering the guided $1.71-$1.74 Q4 EPS plus a credible initial FY27 framework should let the stock grind toward the $170-175 consensus zone; a haircut to FY27 guidance or soft order commentary after a 32% six-month run would compress the multiple quickly, because 22.2x EV/EBITDA offers no valuation cushion. In short, this is an 'earnings must keep arriving' stock right now, not a misunderstood one.

As of 2026-09-13, the technical read is neutral-to-constructive: RSI(14) of 48.13 is dead center — neither overbought nor oversold — while the price of $146.93 sits 2.96% below its 20-day SMA (~$151.4), 2.56% above its 50-day SMA (~$143.3), and 11.67% above its 200-day SMA (~$131.6). That is a short-term pullback inside an intact medium- and long-term uptrend, not a breakdown. The magnitude of the pullback is modest (-0.88% over one month, -2.61% over one week) after a +31.76% six-month run, which argues for patience rather than urgency. The 50-day around $143 is the first support to watch and a reasonable accumulation zone; a close below the 200-day (~$132) would be the signal that the uptrend has actually broken. Note these levels are frozen as of 2026-09-13 and will have moved by the time this is read.

• Fed easing / falling rates: Agilent (beta 1.24) is a high-quality, cash-generative compounder that typically sees multiple expansion when the discount rate falls — the live brief explicitly flags this as a tailwind for life-science tools with expanding operating margins.
• Biopharma and academic lab budget pressure: cost-control and productivity mandates are a secular tailwind for lab automation, mass spectrometry and digital pathology where Agilent is taking share, but also a headwind if R&D budgets are cut outright.
• China and Europe instrument purchasing cycles: high-end instrument capex is discretionary and sensitive to stimulus timing, local policy and FX — the single biggest swing factor in Agilent's growth rate, and one the brief says remains under monitoring.
• Tariffs and trade policy / supply-chain cost inflation on hardware: instrument manufacturing has meaningful cross-border content, so tariff changes can hit gross margin in a business that just posted a 55.5% gross margin quarter.
• Healthcare/medtech sector rotation: diagnostics and research tools are viewed as defensive quality within healthcare, and capital has rotated toward profitable, margin-expanding names as macro uncertainty persists.

• Q4 and full-year FY26 results, tentatively 2026-11-23: management guided Q4 adjusted EPS to $1.71-$1.74 and FY26 to $6.18-$6.21; the key swing factor is initial FY27 guidance and any order-book/China commentary.
• Management's September 2026 appearance at the J.P. Morgan U.S. All Stars Conference — near-term read on order rates and demand momentum.
• New product ramps and regulatory wins: the U.S. launch of the S540MD Slide Scanner System, the Cary 635 FTIR Spectrometer introduction in early September 2026, and summer FDA/international approvals for pharmDx diagnostic assays.
• Further analyst target revisions — post-earnings targets now cluster at $170-$190 (JPM $190, RBC $185, TD Cowen $180, Barclays $175) versus a $146.93 price as of 2026-09-13; continued positive revisions can pull the multiple up.
• Capital deployment: $1.758B of cash, 0.54 debt/equity and strong FCF leave room for buybacks or bolt-on M&A, though long-term debt did rise to $3.645B in Q3 FY26 from $3.05B in Q2 FY26.

• Valuation/expectations risk: after a +31.76% six-month run, 22.2x EV/EBITDA and 28.9x TTM GAAP earnings leave little room for a miss — the stock sold off modestly even into a strong beat and raise.
• Geographic demand risk: China and Europe high-end instrument purchasing remains the biggest uncertainty in the growth rate, and a stall there would break the five-quarter run of 7-10% YoY revenue growth.
• Biopharma R&D budget compression and lab consolidation could slow order growth, especially in early-stage biotech where funding remains choppy.
• GAAP-to-adjusted earnings gap: TTM GAAP EPS of $5.11 vs. FY26 adjusted guidance of ~$6.20 is a ~$1.10 gap driven by amortization/SBC-type adjustments — if that gap narrows, headline multiples look materially fuller than they appear.
• Rising debt and tariff/supply-chain cost inflation: long-term debt climbed to $3.645B in Q3 FY26 from $3.05B in Q2 FY26, and hardware gross margins (55.5% in Q3 FY26) are exposed to tariff and component-cost swings.

Agilent is a genuinely high-quality, cash-generative life-science tools franchise coming out of a real demand trough — five straight quarters of 7-10% YoY revenue growth, gross margin up ~290bps YoY in Q3 FY26, a raised FY26 EPS guide, a 2.05 current ratio, 0.54 debt/equity, negative accruals (-1.12%, so cash earnings exceed reported profit) and $1.25B of TTM free cash flow. At $146.93 you pay 23.7x FY26 adjusted EPS, below the stock's own 31.6x five-year average P/E, which is a fair-to-slightly-attractive price for this quality. The catch is that the easy money has been made in the price (up 31.8% in six months, ~10% off the 52-week high) while EV/EBITDA of 22.2x is a premium to tools peers — so this is a business I want to own on pullbacks into the $140s rather than chase at $147, with the late-November Q4 print and FY27 guide as the near-term arbiter.

I applied a 25.5x P/E — deliberately set between the current 23.7x forward multiple on FY26 adjusted EPS and the 5-year average trailing P/E of 31.6x — to a blended next-twelve-months adjusted EPS of roughly $6.60 (Q4 FY26 guidance midpoint of $1.725 plus FY27 consensus quarters growing ~10-12% off the $6.18-$6.21 FY26 base), which yields ~$168. Cross-check: that implies about 22x forward EV/EBITDA on ~$2.3B of FY27 EBITDA, roughly in line with large-cap life-science tools peers and consistent with a mid-to-high-single-digit organic grower with expanding margins and a fortress balance sheet.